%0 Journal Article
%T Recurrent and Fixed Neutrophilic Dermatosis Associated With Dasatinib
%A Joel C. Bergman
%A Margaret-Mary Keating
%A Peter R. Hull
%A Thai Yen Ly
%J Journal of Cutaneous Medicine and Surgery
%@ 1615-7109
%D 2018
%R 10.1177/1203475418775663
%X Dasatinib is a tyrosine kinase inhibitor indicated for the treatment of chronic myeloid leukemia (CML). Skin rashes are common, occurring in about a quarter of patients treated, and are generally mild. The commonest rash is a keratosis pilaris-like eruption. A neutrophilic dermatosis has rarely been reported. We report a patient whose CML was successfully treated with dasatinib and who several years later developed episodes of a neutrophilic dermatosis recurring at the same sites. This report extends the clinical spectrum of neutrophilic dermatoses to include dasatinib-induced recurrent and fixed erythematous plaques
%K dasatinib
%K neutrophilic dermatosis
%K fixed drug eruption
%K Sweet disease
%K recurrent
%U https://journals.sagepub.com/doi/full/10.1177/1203475418775663